Flagship Pioneering is staking out a new home base in Asia, recruiting a longtime McKinsey vet — and a colleague to Flagship CEO Noubar Afeyan — to start working on a fresh set of strategic deals in the region for its portfolio of biotechs. The move to tap André Andonian for the role of Singapore chair comes after a move into London earlier in the year underscored Flagship’s ambitions outside the US.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.